NervGen Pharma Corp. (NGEN)
$1.73-1.14%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $142M
- Beta
- 0.73
- P/E (TTM)
- -9.25
- Short % float
- 9.06%
- Days to cover
- 11.3
- SI change
- +6.2%
- 1W
- -2.81%
- 1M
- -19.91%
- vs SPY 1W
- -3.97%
- vs SPY 1M
- -22.90%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on NGEN?
- LOPJLB’s latest quantitative signal on NervGen Pharma Corp. Common stock (NGEN) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is NGEN in?
- NervGen Pharma Corp. Common stock (NGEN) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does NervGen Pharma Corp. Common stock (NGEN) do?
- NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer…